Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.63 |
| ▸ | SPHK2 | Q9NRA0 | 14/20 | 0.61 |
| ▸ | SPHK1 | Q9NYA1 | 14/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798847 | 1.00 | HRH3 (0.63) | HRH3SPHK2SPHK1KDM4EALDH1A1 | |
| SCHEMBL4809162 | 0.96 | HRH3 (0.68) | HRH3SPHK2SPHK1KDM4EALDH1A1 | |
| SCHEMBL4809169 | 0.96 | HRH3 (0.68) | HRH3SPHK2SPHK1KDM4EALDH1A1 | |
| SCHEMBL6797294 | 0.82 | SPHK2 (0.62) | HRH3SPHK2SPHK1 | |
| SCHEMBL6797298 | 0.82 | SPHK2 (0.62) | HRH3SPHK2SPHK1 | |
| SCHEMBL25685938 | 0.82 | SPHK2 (0.61) | HRH3SPHK2SPHK1 | |
| SCHEMBL7279837 | 0.81 | SPHK2 (0.60) | SPHK2SPHK1OPRD1 | |
| SCHEMBL29471350 | 0.81 | SPHK2 (0.60) | SPHK2SPHK1OPRD1 | |
| SCHEMBL9372352 | 0.81 | HRH3 (0.63) | HRH3SPHK2SPHK1 | |
| SCHEMBL6807045 | 0.81 | HRH3 (0.63) | HRH3SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1475373-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1471060-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6528504-B2 | Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. | AJINOMOTO CO., INC. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | AJINOMOTO CO., INC. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-1142884-A1 | OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | CACNG5, GRIK5, KCNB1 | HRH3 250/4885SPHK2 734/4885SPHK1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.